In breast cancer, the pharmacological inhibition of PPIA may provide promising and unexpected results in cancer biology, in part by targeting the PPIA/CrkII axis that can modulate the host antitumor immune escape (Davra et al., 2020). Here, CRK is linked to breast cancer.